1. Home
  2. PGEN vs ESPR Comparison

PGEN vs ESPR Comparison

Compare PGEN & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGEN
  • ESPR
  • Stock Information
  • Founded
  • PGEN 1998
  • ESPR 2008
  • Country
  • PGEN United States
  • ESPR United States
  • Employees
  • PGEN N/A
  • ESPR N/A
  • Industry
  • PGEN Biotechnology: Pharmaceutical Preparations
  • ESPR Biotechnology: Pharmaceutical Preparations
  • Sector
  • PGEN Health Care
  • ESPR Health Care
  • Exchange
  • PGEN Nasdaq
  • ESPR Nasdaq
  • Market Cap
  • PGEN 493.0M
  • ESPR 445.6M
  • IPO Year
  • PGEN N/A
  • ESPR 2013
  • Fundamental
  • Price
  • PGEN $4.14
  • ESPR $2.79
  • Analyst Decision
  • PGEN Buy
  • ESPR Buy
  • Analyst Count
  • PGEN 5
  • ESPR 6
  • Target Price
  • PGEN $7.50
  • ESPR $6.50
  • AVG Volume (30 Days)
  • PGEN 18.8M
  • ESPR 6.1M
  • Earning Date
  • PGEN 08-12-2025
  • ESPR 11-06-2025
  • Dividend Yield
  • PGEN N/A
  • ESPR N/A
  • EPS Growth
  • PGEN N/A
  • ESPR N/A
  • EPS
  • PGEN N/A
  • ESPR N/A
  • Revenue
  • PGEN $4,340,000.00
  • ESPR $268,125,000.00
  • Revenue This Year
  • PGEN $253.63
  • ESPR $10.59
  • Revenue Next Year
  • PGEN $699.64
  • ESPR N/A
  • P/E Ratio
  • PGEN N/A
  • ESPR N/A
  • Revenue Growth
  • PGEN N/A
  • ESPR N/A
  • 52 Week Low
  • PGEN $0.65
  • ESPR $0.69
  • 52 Week High
  • PGEN $5.23
  • ESPR $3.94
  • Technical
  • Relative Strength Index (RSI)
  • PGEN 64.19
  • ESPR 78.30
  • Support Level
  • PGEN $3.89
  • ESPR $2.37
  • Resistance Level
  • PGEN $5.23
  • ESPR $2.73
  • Average True Range (ATR)
  • PGEN 0.36
  • ESPR 0.16
  • MACD
  • PGEN -0.09
  • ESPR 0.02
  • Stochastic Oscillator
  • PGEN 32.30
  • ESPR 99.29

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Share on Social Networks: